| RÁČIL, Zdeněk, Eva KORIŤÁKOVÁ, Tomasz SACHA, Hana KLAMOVA, Petra BELOHLAVKOVA, Edgar FABER, Delphine REA, Ludmila MALASKOVA, Jiřina PROCHÁZKOVÁ, Daniela ŽÁČKOVÁ, Jaroslava VOGLOVA, Joanna WACLAW, Petr CETKOVSKY, Pavel ZAK and Jiří MAYER. Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy. American Journal of Hematology. Hoboken: John Wiley & Sons, 2018, vol. 93, No 10, p. "E342"-"E345", 4 pp. ISSN 0361-8609. Available from: https://dx.doi.org/10.1002/ajh.25232. |
Other formats:
BibTeX
LaTeX
RIS
@article{1478081,
author = {Ráčil, Zdeněk and Koriťáková, Eva and Sacha, Tomasz and Klamova, Hana and Belohlavkova, Petra and Faber, Edgar and Rea, Delphine and Malaskova, Ludmila and Procházková, Jiřina and Žáčková, Daniela and Voglova, Jaroslava and Waclaw, Joanna and Cetkovsky, Petr and Zak, Pavel and Mayer, Jiří},
article_location = {Hoboken},
article_number = {10},
doi = {http://dx.doi.org/10.1002/ajh.25232},
keywords = {nilotinib therapy},
language = {eng},
issn = {0361-8609},
journal = {American Journal of Hematology},
title = {Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy},
volume = {93},
year = {2018}
}
TY - JOUR
ID - 1478081
AU - Ráčil, Zdeněk - Koriťáková, Eva - Sacha, Tomasz - Klamova, Hana - Belohlavkova, Petra - Faber, Edgar - Rea, Delphine - Malaskova, Ludmila - Procházková, Jiřina - Žáčková, Daniela - Voglova, Jaroslava - Waclaw, Joanna - Cetkovsky, Petr - Zak, Pavel - Mayer, Jiří
PY - 2018
TI - Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy
JF - American Journal of Hematology
VL - 93
IS - 10
SP - "E342"-"E345"
EP - "E342"-"E345"
PB - John Wiley & Sons
SN - 03618609
KW - nilotinib therapy
N2 - Impaired glucose metabolism (IGM) with hyperglycemia represents one of the most frequently observed adverse events (AE) during nilotinib therapy of chronic myeloid leukemia (CML). The exact mechanism of IGM remains controversial. Although a case report has shown a decrease in insulin secretion1 , our previous pilot data suggested development of insulin resistance as a possible mechanism.2 In this prospective study we aimed to confirm results from our pilot study using a larger cohort of CML patients treated with nilotinib and to compare results with data obtained on control groups receiving imatinib and dasatinib.
ER -
RÁČIL, Zdeněk, Eva KORIŤÁKOVÁ, Tomasz SACHA, Hana KLAMOVA, Petra BELOHLAVKOVA, Edgar FABER, Delphine REA, Ludmila MALASKOVA, Jiřina PROCHÁZKOVÁ, Daniela ŽÁČKOVÁ, Jaroslava VOGLOVA, Joanna WACLAW, Petr CETKOVSKY, Pavel ZAK and Jiří MAYER. Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy. \textit{American Journal of Hematology}. Hoboken: John Wiley \&{} Sons, 2018, vol.~93, No~10, p.~''E342''-''E345'', 4 pp. ISSN~0361-8609. Available from: https://dx.doi.org/10.1002/ajh.25232.
|
